WO2019024933A1 - Cellule car nk ciblant gpc3 - Google Patents
Cellule car nk ciblant gpc3 Download PDFInfo
- Publication number
- WO2019024933A1 WO2019024933A1 PCT/CN2018/098623 CN2018098623W WO2019024933A1 WO 2019024933 A1 WO2019024933 A1 WO 2019024933A1 CN 2018098623 W CN2018098623 W CN 2018098623W WO 2019024933 A1 WO2019024933 A1 WO 2019024933A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- cancer
- gpc3
- domain
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims abstract description 251
- 102100032530 Glypican-3 Human genes 0.000 claims abstract description 90
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 89
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims abstract description 87
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 33
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 238000009169 immunotherapy Methods 0.000 claims abstract description 14
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 28
- 230000011664 signaling Effects 0.000 claims description 24
- 208000014018 liver neoplasm Diseases 0.000 claims description 23
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 22
- 201000007270 liver cancer Diseases 0.000 claims description 22
- 102100024263 CD160 antigen Human genes 0.000 claims description 21
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 21
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 21
- 102100032816 Integrin alpha-6 Human genes 0.000 claims description 21
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 21
- 230000003834 intracellular effect Effects 0.000 claims description 21
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 18
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 18
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims description 17
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 17
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 17
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims description 14
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims description 14
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims description 14
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 14
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 14
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 claims description 14
- 102100039904 Integrin alpha-D Human genes 0.000 claims description 14
- 102100022341 Integrin alpha-E Human genes 0.000 claims description 14
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 14
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 14
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 14
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 14
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 14
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 14
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 13
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 13
- 238000002619 cancer immunotherapy Methods 0.000 claims description 13
- 230000000139 costimulatory effect Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 210000004698 lymphocyte Anatomy 0.000 claims description 10
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229940044683 chemotherapy drug Drugs 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 8
- 102000014128 RANK Ligand Human genes 0.000 claims description 8
- 108010025832 RANK Ligand Proteins 0.000 claims description 8
- 108700010039 chimeric receptor Proteins 0.000 claims description 8
- 108010056102 CD100 antigen Proteins 0.000 claims description 7
- 108010017009 CD11b Antigen Proteins 0.000 claims description 7
- 102100038077 CD226 antigen Human genes 0.000 claims description 7
- 102100027207 CD27 antigen Human genes 0.000 claims description 7
- 101150013553 CD40 gene Proteins 0.000 claims description 7
- 108010062802 CD66 antigens Proteins 0.000 claims description 7
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 7
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 claims description 7
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 7
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims description 7
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 7
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 7
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims description 7
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 7
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 7
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 7
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims description 7
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 7
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 7
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 7
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 7
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 7
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 7
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 7
- 108010041100 Integrin alpha6 Proteins 0.000 claims description 7
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims description 7
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 7
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 7
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 7
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 7
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 7
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 7
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 7
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 7
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 7
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims description 7
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims description 7
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 7
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 7
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 7
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 7
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 7
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 7
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 7
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 7
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 7
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 claims description 7
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 6
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 238000002659 cell therapy Methods 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 230000000779 depleting effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 102100035793 CD83 antigen Human genes 0.000 claims description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 4
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims description 4
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 4
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 101710145634 Antigen 1 Proteins 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 108091008874 T cell receptors Proteins 0.000 claims description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 208000012018 Yolk sac tumor Diseases 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 208000001991 endodermal sinus tumor Diseases 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical group C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 230000008685 targeting Effects 0.000 abstract description 8
- 230000002147 killing effect Effects 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 16
- 238000007920 subcutaneous administration Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 15
- 230000000259 anti-tumor effect Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 10
- 229960003787 sorafenib Drugs 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 9
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 241000713666 Lentivirus Species 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 238000011789 NOD SCID mouse Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 210000003712 lysosome Anatomy 0.000 description 6
- 230000001868 lysosomic effect Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000022534 cell killing Effects 0.000 description 5
- 238000002784 cytotoxicity assay Methods 0.000 description 5
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000001398 Granzyme Human genes 0.000 description 4
- 108060005986 Granzyme Proteins 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108010056030 retronectin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108050007237 Glypican-3 Proteins 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000003874 Simpson-Golabi-Behmel syndrome Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 102000050327 human TNFRSF9 Human genes 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000005917 in vivo anti-tumor Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100030704 Interleukin-21 Human genes 0.000 description 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000002946 Simpson-Golabi-Behmel syndrome type 1 Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 101150039713 gpc3 gene Proteins 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- ZGVSETXHNHBTRK-UDJLNJFBSA-N solanine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZGVSETXHNHBTRK-UDJLNJFBSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Abstract
L'invention concerne une cellule NK à récepteur d'antigène chimérique exprimant une reconnaissance spécifique pour GPC3 et sa méthode de préparation, ainsi qu'une utilisation de la cellule dans la prévention et/ou le traitement de cancers, en particulier un cancer exprimant GPC3. L'invention concerne également une utilisation de la cellule NK en tant qu'agent thérapeutique cellulaire de ciblage et/ou en immunothérapie adoptive de cancers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710661765.3 | 2017-08-04 | ||
CN201710661765 | 2017-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019024933A1 true WO2019024933A1 (fr) | 2019-02-07 |
Family
ID=65232303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/098623 WO2019024933A1 (fr) | 2017-08-04 | 2018-08-03 | Cellule car nk ciblant gpc3 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109385403B (fr) |
WO (1) | WO2019024933A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3747433A4 (fr) * | 2018-02-02 | 2021-12-22 | Cafa Therapeutics Limited | Association d'immunothérapie cellulaire |
WO2022028623A1 (fr) | 2020-08-07 | 2022-02-10 | 佧珐药业有限公司 | Cellules modifiées et procédé de modification de cellules |
WO2022214089A1 (fr) | 2021-04-08 | 2022-10-13 | 克莱格医学有限公司 | Utilisation d'immunothérapie cellulaire |
WO2023274303A1 (fr) | 2021-06-29 | 2023-01-05 | 科济生物医药(上海)有限公司 | Polypeptide chimérique pour la régulation de l'activité physiologique cellulaire |
WO2023178333A1 (fr) * | 2022-03-18 | 2023-09-21 | WUGEN, Inc. | Constructions de récepteurs chimériques améliorées pour cellules nk |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112175085B (zh) * | 2019-06-14 | 2022-11-04 | 厦门大学 | 抗gpc3抗体及其用途 |
CN110627909B (zh) * | 2019-08-28 | 2021-03-30 | 中国人民解放军第二军医大学 | 一种特异性活化nk细胞的嵌合抗原受体及其应用 |
CN110684117B (zh) * | 2019-09-25 | 2021-01-01 | 汕头普罗凯融生物医药科技有限公司 | 一种car嵌合抗原受体序列及应用其的car-nk细胞 |
CN112608905A (zh) * | 2021-01-18 | 2021-04-06 | 梅奥(浙江)细胞工程有限责任公司 | 靶向gpc3的car-nk细胞及其制备方法和应用 |
WO2022198611A1 (fr) * | 2021-03-25 | 2022-09-29 | 汕头普罗凯融生物医药科技有限公司 | Séquence de récepteur antigénique chimérique car et cellules car-nk l'utilisant |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104140974A (zh) * | 2013-05-08 | 2014-11-12 | 上海益杰生物技术有限公司 | 编码gpc-3嵌合抗原受体蛋白的核酸及表达gpc-3嵌合抗原受体蛋白的t淋巴细胞 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015142661A1 (fr) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Récepteur d'antigène chimèrique régulable |
EP3141603A4 (fr) * | 2014-05-08 | 2017-12-27 | Chugai Seiyaku Kabushiki Kaisha | Agent thérapeutique ciblant le gpc3 pour administration à des patients pour qui la thérapie par agent thérapeutique ciblant le gpc3 est efficace |
US11376326B2 (en) * | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
DK3333192T3 (da) * | 2015-08-03 | 2021-05-31 | Cafa Therapeutics Ltd | Antistof imod glypican-3 og anvendelse deraf |
US20180371052A1 (en) * | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
-
2018
- 2018-08-03 CN CN201810879882.1A patent/CN109385403B/zh active Active
- 2018-08-03 WO PCT/CN2018/098623 patent/WO2019024933A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104140974A (zh) * | 2013-05-08 | 2014-11-12 | 上海益杰生物技术有限公司 | 编码gpc-3嵌合抗原受体蛋白的核酸及表达gpc-3嵌合抗原受体蛋白的t淋巴细胞 |
Non-Patent Citations (2)
Title |
---|
LI, KEYU ET AL.: "Chimeric Antigen Receptor-Engineered T Cells for Liver Cancers, Progress and Obstacles", TUMOR BIOLOGY, vol. 39, no. 3, 28 March 2017 (2017-03-28), pages 1 - 8, XP055571345, ISSN: 1423-0380 * |
YU , MIN ET AL.: "Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma", MOLECULAR THERAPY, vol. 26, no. 2, 7 February 2018 (2018-02-07), pages 366 - 378, XP055565104, ISSN: 1525-0016 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3747433A4 (fr) * | 2018-02-02 | 2021-12-22 | Cafa Therapeutics Limited | Association d'immunothérapie cellulaire |
WO2022028623A1 (fr) | 2020-08-07 | 2022-02-10 | 佧珐药业有限公司 | Cellules modifiées et procédé de modification de cellules |
WO2022214089A1 (fr) | 2021-04-08 | 2022-10-13 | 克莱格医学有限公司 | Utilisation d'immunothérapie cellulaire |
WO2023274303A1 (fr) | 2021-06-29 | 2023-01-05 | 科济生物医药(上海)有限公司 | Polypeptide chimérique pour la régulation de l'activité physiologique cellulaire |
WO2023178333A1 (fr) * | 2022-03-18 | 2023-09-21 | WUGEN, Inc. | Constructions de récepteurs chimériques améliorées pour cellules nk |
Also Published As
Publication number | Publication date |
---|---|
CN109385403A (zh) | 2019-02-26 |
CN109385403B (zh) | 2024-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019024933A1 (fr) | Cellule car nk ciblant gpc3 | |
US20230340113A1 (en) | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF | |
US11564945B2 (en) | Chimeric antigen receptor and use thereof | |
AU2015329444B2 (en) | CAR expression vector and CAR-expressing T cells | |
JP6285553B2 (ja) | 抗cd30キメラ抗原受容体およびその使用 | |
CN105713881B (zh) | 双靶向gpc3和asgpr1的转基因免疫效应细胞及其应用 | |
CN111247242A (zh) | 嵌合抗原受体(CARs)、组合物及其使用方法 | |
JP7222600B2 (ja) | 腫瘍細胞に特異的なキメラ抗原レセプター | |
TW201940520A (zh) | 攝護腺特異性膜抗原嵌合抗原受體及其用途 | |
CN106535925A (zh) | 基于car的免疫治疗 | |
WO2019052562A1 (fr) | Protéine de fusion d'une il-4r et son utilisation | |
KR20230129979A (ko) | 수지상 세포 활성화 키메라 항원 수용체 및 이의 용도 | |
CN113402619B (zh) | 一种靶向B7H3共表达IL-21的全人源嵌合抗原受体、iNKT细胞及其用途 | |
CN109652378A (zh) | 一种功能增强的通用型car-t细胞及其制备方法和用途 | |
CN110404061B (zh) | 改进的t细胞治疗方法 | |
CN109722437A (zh) | 一种通用型car-t细胞及其制备方法和用途 | |
CN113896801B (zh) | 靶向人Claudin18.2和NKG2DL的嵌合抗原受体细胞及其制备方法和应用 | |
CN113416260B (zh) | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 | |
WO2022033483A1 (fr) | Cellule effectrice immunitaire multifonctionnelle et son utilisation | |
CN111542547B (zh) | 对bdca2抗原具有特异性的嵌合抗原受体 | |
CN116041546A (zh) | 嵌合抗原受体、分离的核酸、重组载体、car-t细胞及其应用 | |
CN108251442A (zh) | Flt3嵌合抗原受体及其应用 | |
CN115916963A (zh) | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 | |
CN114891123B (zh) | 一种基于CD79b人源化抗体的嵌合抗原受体及其应用 | |
CN114149978B (zh) | 制备car-t细胞的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18841057 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18841057 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18841057 Country of ref document: EP Kind code of ref document: A1 |